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It seems we have reached a pleateau when it comes to adding3 or more cytotoxic therapies together for lung cancer
treatment. We are now in an era of near infinite options for
testing of targeted therapies with or without singlet or doublet
cytotoxics. Although certain molecular and phenotypic fea-
tures bode well for efficacy with single-agent therapy (e.g.,
EGFR mutation and EGFR tyrosine kinase inhibitors or
adenocarcinoma and pemetrexed), most lung cancers fail to
show dramatic responses to currently available agents—and
even less commonly is there a curative potential with sys-
temic therapy for advanced multifocal disease. One proposed
barrier to achieve this goal may be the existence of putative
cancer stem cell (CSC). A tumor is thought to be composed
of a bulk of differentiated cancer cells and a small pluripotent
fraction of self-renewing CSCs.1 It is these CSCs that are
hypothesized to be more resistant to most systemic and
radiotherapies compared with the bulk mass of tumor cells.1
After treatment, when there is regrowth or recurrence of
tumor, the bulk cancer cells repopulate from differentiation of
CSCs, in part from increased signaling of Hedgehog1 and
Notch in CSCs.2 Similarly, the most effective way to bring us
closer to curative therapy for advanced/metastatic lung cancer
will be a combination of cytotoxic or appropriate molecular-
targeted therapy to debulk the majority of tumor cells and
delivery of Hedgehog and Notch signaling inhibitors to elim-
inate the CSCs to prevent tumor growth/recurrence.1
Summary of Research Presentations
An overview of the Hedgehog Signaling Pathway
(HSP) and Notch Signaling Pathway (NSP) was provided by
Dr. Rudin. Since last year, some clinical results on at least
four SMO antagonists (GDC-0449, LDE-225, BMS-833923,
and IPI-926) have now been formally presented at national
meetings. Clinical activity in medulloblastoma with GDC-
0449 and LDE-225 was highlighted along with a mechanism
of acquired drug resistance. Rationale behind targeting NSP
was presented with a brief overview of two agents in devel-
opment (MK-0752 and R04929097).
Targeting the Hedgehog Signaling Pathway:
Smoothened Antagonists
Dr. Rudin then discussed in greater detail, the preclin-
ical and clinical development of IPI-926, a SMO antagonist
with improved solubility, chemical stability, potency, selec-
tivity, and metabolic stability over the naturally occurring
SMO antagonist, cyclopamine. The phase I study is still
ongoing with 24 basal cell carcinoma (BCC) and 36 non-
BCC patients enrolled.3 The main dose-limiting toxicity is
asymptomatic, reversible grade 3 transaminitis, and primary-
related adverse events (AEs) are grade 1 and grade 2 fatigue
and nausea. The agent has near dose proportional pharmaco-
kinetics (PK) and evidence of on-target pathway suppression.
Clinical partial responses have been observed in patients with
BCC. A phase II single-agent study in chondrosarcoma was
recently launched (www.clinicaltrials.gov).
Dr. Mita summarized the preclinical and clinical devel-
opment of LDE-225. The phase I study is still ongoing with
8 BCC and 58 non-BCC patients enrolled. The main dose-
limiting toxicity is reversible grade 3/4 creatinine phospho-
kinase elevation and asthenia, and primary-related AEs are
grade 1 and grade 2 nausea, dysguesia, and muscle spasms.
The agent has near dose proportional PK and, similar to other
SMO antagonists, there is evidence of on-target pathway
suppression. Clinical responses have been observed in pa-
tients with BCC and medulloblastoma with one patient with
non-small cell lung cancer (NSCLC) NOS maintaining stable
disease more than 15 months.
Next, I presented the preclinical and clinical develop-
ment of GDC-0449, a synthetic SMO antagonist that has
completed phase I study with no major safety signals with
dosing out to at least 26 months4 and demonstrated clinical
activity as a single agent in locally advanced and metastatic
BCC.5 For cancers without a SMO or Patched mutation
(resulting in constitutive activation of the HSP), a combina-
tion of HSP inhibition using a SMO antagonist plus other
systemic therapies would likely be necessary to both tackle
the CSC and bulk tumor.1 GDC-0449 at a dose of 150 mg
once daily is in phase II studies in combination with
chemotherapy and/or targeted agents in several different
tumor types, including small cell lung cancer (SCLC)
(www.clinicaltrials.gov).
Targeting the Notch Signaling Pathway: -
Secretase Inhibitors
Dr. Gibbons discussed preclinical data on how mi-
croRNA, specifically miR-200 expression, is inversely cor-
related with epithelial-mesenchymal transition (EMT). Mi-
croRNAs are short, 19-24 nucleotide noncoding RNAs
involved in a variety of biologic regulatory processes and
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implicated in carcinogenesis.6 Preclinical data were presented
to show how miR-200 regulates Notch/Jag signaling in can-
cer and development. Two trials involving the secretase
inhibitor, RO4929097, were highlighted. The first is a main-
tenance study for nonprogressing advanced NSCLC patients
after first-line therapy with biological correlates planned
including evaluation of Notch expression and microRNA
levels. The second study is a phase I/II in combination with
erlotinib in advanced-stage NSCLC.
Dr. Keedy presented mechanisms of Notch inhibition
and summarized the -secretase inhibitors currently in clini-
cal development. One pending study involves MK-0752 in
combination with erlotinib in previously treated, advanced
NSCLC. Data were also presented demonstrating a potential
role for Notch receptor or ligand inhibitors with examples of
agents in preclinical and clinical studies.
Future Directions
Data presented by multiple investigators provide the
landscape of recent development of agents targeting the HSP
and NSP. Challenges that lay ahead include matching the
right tumor genotype and phenotype with the right agent or
combination of agents. For HSP inhibition in lung cancer, the
results of E1508 trial that combines a SMO antagonist with
cytotoxic chemotherapy in first-line therapy for SCLC are
eagerly awaited. If successful, it will likely catapult addi-
tional combination studies involving SMO antagonists in this
lung cancer subtype and other solid tumors. NSP inhibition
studies are still fairly nascent in lung cancer. The preclinical
rationale for targeting NSP is sound, and like all promising
pathway targets, it remains to be seen how these initial
studies play out and will shape their future development as
therapeutics in lung cancer. Hopefully, there is good synergy
with systemic cytotoxics and/or targeted therapy with these
HSP and NSP inhibitors so that we may see whether targeting
both bulk tumor mass and putative CSCs leads to the ultimate
goal for treating advanced lung cancers: cure.
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